User benefits include instant quotations and documentation, exclusive rates and the ability to make alterations and immediately obtain revised documentation
The Life Science team at Jardine Lloyd Thompson Limited (JLT) has worked in partnership with HDI-Gerling to develop a web based application that is set to revolutionalise the purchasing and management of clinical trials insurance by providing a faster, more efficient service that puts the insurance buyer in control. Instant quotations and documentation, the ability to make instant changes and obtain revised certificates, and improved management information through 24/7 access to past and present trials are just a few of the benefits.
James Bird, Partner in JLT's Life Science and Chemical Industry Practice that led the development of the new service explains, "Clinical trials are a critical part of the process in developing new products in the competitive pharmaceuticals industry. As part of this process it is often necessary to undertake trials in a number of different countries. This creates an additional insurance burden as each country requires evidence of insurance, often in the local language and that satisfies local regulations. If changes are then required, for example to extend the period of the trial, delays in obtaining revised certification can delay the trials.
"The current methods for purchasing clinical trials insurance are time consuming, inefficient and a minefield to manage effectively. That is why we set about developing an intuitive system to make it easier for clients to buy and manage their clinical trials insurance and ensure they meet regulatory requirements".
The Clinical Trials Insurance Portal will initially offer cover in selective European countries but is quickly being extended to include more countries and other regions.
Richard Taylor, HDI-Gerling’s UK Managing Director, says, "HDI and JLT’s experience in this market place combined with our understanding of insurance requirements, process and claims management and the work we have undertaken to understand the needs of clients and the international issues they face have resulted in a product that creates real efficiencies, better management information and enhances the user’s experience and ability to manage this process."
James Bird concludes, "We spent a lot of time working on the rating engine to ensure that almost all enquiries will receive instant quotations. Even where an enquiry needs to be referred the client will receive a quick response and then be able to benefit from the system in terms of documentation, management information and if they want to make changes to the cover".
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.